grant
Project 1: Delta immune Ecology of NSCLC
Organization H. LEE MOFFITT CANCER CTR & RES INSTLocation TAMPA, UNITED STATESPosted 15 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025AffectAntitumor ResponseAutopsyBiological MarkersBionomicsBiopsyBloodBlood Reticuloendothelial SystemC-K-RASCT-26CT26CalibrationCancer PatientCancer TreatmentCancersCell BodyCellsCheckpoint inhibitorClinicalClinical DataClinical ResearchClinical StudyClinical TrialsColon CancerColon CarcinomaCombined Modality TherapyDataDevelopmentDiseaseDisorderDrugsEcological ChangeEcologyEvolutionFutureGoalsHumanImmuneImmune checkpoint inhibitorImmune mediated therapyImmunesImmunologically Directed TherapyImmunotherapeutic agentImmunotherapyK-RAS2AK-RAS2BK-RasK-Ras 2AK-Ras-2 OncogeneKRASKRAS2KRAS2 geneKeytrudaKi-RASLung NeoplasmsLung TumorMEKsMachine LearningMalignant CellMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMath ModelsMedicationMiceMice MammalsModelingModern ManMultimodal TherapyMultimodal TreatmentMurineMusNSCLCNSCLC - Non-Small Cell Lung CancerNatureNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaOncogene K-RasPD-1 antibodyPD1 antibodyPathway interactionsPatientsPharmaceutical PreparationsPhase 1/2 trialPhase I/II TrialPulmonary NeoplasmsRAS inhibitionRASK2RandomizedResearch SpecimenResistanceResistance developmentResistant developmentSamplingSignal PathwaySpecimenStaining methodStainsStudy modelsSystemT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell responseT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-cell therapeuticsT-cell transfer therapyTestingThoracic OncologyTissue DonationsTreatment ProtocolsTreatment RegimenTreatment ScheduleTumor CellTumor-Infiltrating LymphocytesWorkaPD-1aPD1adoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyanalysis pipelineanti programmed cell death 1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-cancer therapyanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyanti-tumor responseantiPD-1armbio-markersbiologic markerbiomarkercancer cellcancer in the coloncancer progressioncancer therapycancer-directed therapyclinical efficacycombination therapycombined modality treatmentcombined treatmentcomputational infrastructurecomputer based predictioncomputer infrastructuredeep learningdeep learning methoddeep learning strategydesigndesigningdeveloping resistancedevelopmentaldrug/agentexperimentexperimental researchexperimental studyexperimentsimmune check point inhibitorimmune drugsimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic therapeuticsimmunotherapeuticsimmunotherapy agentimprovedimproved outcomein vivoinhibitorinhibitor druginhibitor therapeuticinhibitor therapymachine based learningmalignancymathematic modelmathematical modelmathematical modelingmulti-modal therapymulti-modal treatmentmultiplexed imagingmutantnecropsyneoplasm progressionneoplasm/cancerneoplastic cellneoplastic progressionnovelpathwaypatient responsepatient specific responsepembrolizumabphase 1 trialphase I trialpostmortempre-clinicalpreclinicalpredict responsivenesspredicting responsepredictive modelingpreventpreventingprogramsrandomisationrandomizationrandomly assignedresistance mechanismresistantresistant mechanismresponseresponse to therapyresponse to treatmentresponsive patientspatial and temporalspatial temporalspatiotemporalstatisticssynergismtargeted agenttargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic T-cell platformtherapeutic responsetherapy responsetooltreatment responsetreatment responsivenesstreatment strategytumortumor progressionv-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homologwhole slide imagingαPD-1αPD1
Description preview
Summary – Project 1 Project 1 will study the ∆-Ecology of tumor-immune interactions in NSCLC, with a focus on KRAS-mutant cancers. Immunotherapy has demonstrated response rates of 30 to 45%. Most responses are followed by evolution of resistance and progression. Recently we have quantified the immune ecology of these cancers from pre-treatment…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click